RxDoctor Payments Data

Sergio Patton, MD

Internal Medicine · Charlotte, NCNPI 1104321538

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 21 payments — averaging $66.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$205
  • Amarin Pharma, Inc.$185
  • Bayer$147
  • AbbVie$144
  • Boehringer Ingelheim$144
  • Hologic Sales And Service, LLC$141
  • plus $420 from 7 others

What the payments were for

  • Food & beverage$1,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$205
Amarin Pharma, Inc.2$185
Bayer1$147
AbbVie2$144
Boehringer Ingelheim2$144
Hologic Sales And Service, LLC1$141
AstraZeneca1$125
Novartis1$118
Novo Nordisk3$59
Abbott2$47
Pfizer2$38
The Binding Site Inc.1$18
Boston Scientific1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$109,649
Medicare patients
195
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin357$280,541
OzempicSemaglutide197$209,036
EliquisApixaban108$102,667
TrulicityDulaglutide78$93,953
FarxigaDapagliflozin Propanediol93$86,878
MounjaroTirzepatide42$50,018
RybelsusSemaglutide32$38,852
JanuviaSitagliptin Phosphate26$32,192
XareltoRivaroxaban20$23,197
Tresiba Flextouch U-200Insulin Degludec18$20,193
VascepaIcosapent Ethyl23$14,169
Incruse ElliptaUmeclidinium Bromide21$11,472
NexletolBempedoic Acid21$8,180
KerendiaFinerenone12$7,779
Telmisartan-AmlodipineTelmisartan/Amlodipine20$5,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$144$280,541357 claims
Novo NordiskOzempic, Rybelsus$59$247,889229 claims
PfizerEliquis$38$102,667108 claims
AstraZenecaFarxiga$125$86,87893 claims
BayerKerendia$147$7,77912 claims
AbbVieSynthroid$144$2,32038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →